Antitrust to Protect “Small Dealers and Worthy Men”?
As I skimmed through the White House White Paper on innovation (HT: Patently-O), I noticed that a repeated theme in the document is that US . . .
Antitrust to Protect “Small Dealers and Worthy Men”?
Coming Soon: New Merger Guidelines
The possibility of new Merger Guidelines has been much discussed in the antitrust community, particularly in light of appointment of the two new chief agency . . .
How Competitive Is the Health Insurance Market, Really?
Not very, according to the President in his recent health care speech, making the case that lack of competition and for-profit monopolists are what ails . . .
Another Way DOJ Might Pursue “Vigorous Antitrust Enforcement in This Challenging Era”
DOJ’s top antitrust enforcer Christine Varney had hardly gotten settled in her office before she repudiated the existing DOJ guidelines on policing single-firm conduct. In . . .
An Addendum on Jones v. Harris in Response to Professor Birdthistle: Ex Ante Competition, Cognitive Biases and Behavioral Economics
Professor Birdthistle has a very thoughtful reply to my earlier post over at the Conglomerate on Jones v. Harris and behavioral economics. I thank Professor . . .
Jones v. Harris and Some Ramblings on Burdens of Proof, Empirical Evidence, and Behavioral Law and Economics
Much has been made about the importance of Jones v. Harris as a battle in the ongoing war between behavioral economics and rational choice/neoclassical framework . . .
The optimal level of risk is not zero
I have said it before and I’ll say it again: All of this hand wringing over executive compensation seems to exist in a parallel world . . .
BU Antitrust Conference Honoring Professor Joseph Brodley’s Retirement
Professor Joe Brodley, after a long and distinguished career as an antitrust scholar, retired at the end of the Spring 2009 semester. Boston University Law . . .
Thaler’s Unsound Argument About the Public Insurance Option
University of Chicago economist (and behavioralist doyen) Richard Thaler thinks “the question of whether a ‘public option’ should be part of the health care solution” . . .